Treatment for Gram-Negative Bacteremia

Initial Empiric Antibiotic Selection

The American College of Physicians and Infectious Diseases Society of America recommends initiating immediate empiric broad-spectrum antibiotic therapy with an anti-pseudomonal beta-lactam combined with an aminoglycoside for critically ill patients with suspected gram-negative bacteremia, particularly those with sepsis, neutropenia, or suspected multidrug-resistant organisms 1, 2
Critically ill patients with suspected gram-negative bacteremia should receive dual antibiotic therapy with an anti-pseudomonal beta-lactam plus an aminoglycoside to ensure adequate coverage, provide synergistic activity, and reduce resistance development 3, 1
Patients with severe granulocytopenia, sepsis, or known colonization with multidrug-resistant organisms require two antimicrobial agents of different classes 1

Piperacillin-tazobactam is appropriate for gram-negative coverage in settings without high prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae 2
In settings with high ESBL prevalence, carbapenems should be used instead of piperacillin-tazobactam 4

A 14-day course of antibiotic therapy should be reserved for complicated infections including endocarditis, suppurative thrombophlebitis, metastatic infection, or persistent bacteremia beyond 72 hours despite appropriate therapy 1

Once culture and susceptibility results are available, de-escalate from combination therapy to a single appropriate antibiotic based on susceptibility testing 1
The aminoglycoside component can typically be discontinued earlier (after 3-5 days) once clinical improvement is evident and susceptibility results confirm adequate coverage with the beta-lactam alone 5

Patients with severe and persistent granulocytopenia require combination therapy with an anti-pseudomonal beta-lactam plus an aminoglycoside as the standard approach 3, 6

Obtain blood cultures before initiating antibiotics, but do not delay treatment while awaiting results 2
Follow-up blood cultures should be obtained if bacteremia persists beyond 72 hours of appropriate therapy 1
Procalcitonin monitoring may be useful to guide antimicrobial discontinuation, though this approach requires careful clinical correlation 4

Do not use monotherapy in critically ill patients, those with profound neutropenia, or suspected Pseudomonas aeruginosa infection, as outcomes are significantly worse 3
Do not continue combination therapy for the full treatment course once susceptibility results confirm adequate single-agent coverage 1
Emergence of resistance to beta-lactam antibiotics is common and necessitates successive modifications of empiric regimens over time based on local resistance patterns 3